Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

BACKGROUND: The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different adjuvants and priming agents for human immunodeficiency virus (HIV) type 1 (HIV-1) preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseinipour, Mina C, Innes, Craig, Naidoo, Sarita, Mann, Philipp, Hutter, Julia, Ramjee, Gita, Sebe, Modulakgotla, Maganga, Lucas, Herce, Michael E, deCamp, Allan C, Marshall, Kyle, Dintwe, One, Andersen-Nissen, Erica, Tomaras, Georgia D, Mkhize, Nonhlanhla, Morris, Lynn, Jensen, Ryan, Miner, Maurine D, Pantaleo, Giuseppe, Ding, Song, Van Der Meeren, Olivier, Barnett, Susan W, McElrath, M Juliana, Corey, Lawrence, Kublin, James G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823071/
https://www.ncbi.nlm.nih.gov/pubmed/31900486
http://dx.doi.org/10.1093/cid/ciz1239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823071/
https://www.ncbi.nlm.nih.gov/pubmed/31900486
http://dx.doi.org/10.1093/cid/ciz1239

Ejemplares similares